专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08465934B2 Use of protein SATB2 as a marker for colorectal cancer 有权
标题翻译：使用蛋白质SATB2作为结肠直肠癌的标志物
公开(公告)号：US08465934B2
公开(公告)日：2013-06-18
申请号：US13542723
申请日：2012-07-06
申请人： Mathias Uhlén , Fredrik Pontén
发明人： Mathias Uhlén , Fredrik Pontén
IPC分类号： G01N33/53 , G01N33/574
CPC分类号： G01N33/57419 , G01N2333/4703
摘要： The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.
摘要翻译：本发明通过鉴定SATB2蛋白作为该癌症类型的标志物，提供了与直肠癌的检测，表征和预后有关的新方法，手段和用途。

2. 发明授权

US08999656B2 PODXL protein in colorectal cancer 有权
标题翻译： PODXL蛋白在结肠直肠癌中的表达
公开(公告)号：US08999656B2
公开(公告)日：2015-04-07
申请号：US13456354
申请日：2012-04-26
申请人： Karin Jirström , Mathias Uhlén , Fredrik Pontén
发明人： Karin Jirström , Mathias Uhlén , Fredrik Pontén
IPC分类号： G01N33/574 , C07K16/30
CPC分类号： G01N33/57419 , C07K16/22 , C07K16/3046 , C07K2317/76 , G01N2333/705 , G01N2333/90216 , G01N2800/52 , G01N2800/56
摘要： The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.
摘要翻译：本公开提供了一种用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤：：a）评估早先从受试者获得的样品的至少一部分中的PODXL蛋白的量，并确定与评估量相对应的样品值; b）将来自步骤a）的所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）认定所述对象属于所述第二组; 并且如果所述样本值小于或等于所述参考值，则c2）断定所述对象属于所述第一组。还提供了相关用途，手段和治疗方法。

3. 发明申请

US20120028836A1 USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER 有权
标题翻译：使用蛋白质SATB2作为颜色癌症的标记
公开(公告)号：US20120028836A1
公开(公告)日：2012-02-02
申请号：US13278473
申请日：2011-10-21
申请人： Mathias Uhlén , Fredrik Pontén
发明人： Mathias Uhlén , Fredrik Pontén
IPC分类号： C40B30/04 , C07K16/30 , G01N21/76 , G01N33/566 , G01N21/64
CPC分类号： G01N33/57419 , G01N2333/4703
摘要： The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.
摘要翻译：本发明通过鉴定SATB2蛋白作为该癌症类型的标志物，提供了与直肠癌的检测，表征和预后有关的新方法，手段和用途。

4. 发明授权

US08728739B2 RBM3 in colorectal cancer prognostics 有权
标题翻译： RBM3在结肠直肠癌预后中的作用
公开(公告)号：US08728739B2
公开(公告)日：2014-05-20
申请号：US13210816
申请日：2011-08-16
申请人： Mathias Uhlén , Fredrik Pontén , Karin Jirström
发明人： Mathias Uhlén , Fredrik Pontén , Karin Jirström
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： C07K16/18 , A61K31/7068 , A61K39/39533 , A61K45/06 , C07K14/4748 , C07K16/3038 , C07K2317/34 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57407 , G01N33/57419 , A61K2300/00
摘要： The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.
摘要翻译：本发明提供了用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，例如方法，其中第一组受试者的预后优于第二组受试者的预后。该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白或RBM3 mRNA分子的量，并确定对应于评估量的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

5. 发明授权

US08241859B2 Use of protein SATB2 as a marker for colorectal cancer 有权
标题翻译：使用蛋白质SATB2作为结肠直肠癌的标志物
公开(公告)号：US08241859B2
公开(公告)日：2012-08-14
申请号：US13278473
申请日：2011-10-21
申请人： Mathias Uhlén , Fredrik Pontén
发明人： Mathias Uhlén , Fredrik Pontén
IPC分类号： G01N33/53 , G01N33/574
CPC分类号： G01N33/57419 , G01N2333/4703
摘要： The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.
摘要翻译：本发明通过鉴定SATB2蛋白作为该癌症类型的标志物，提供了与直肠癌的检测，表征和预后有关的新方法，手段和用途。

6. 发明申请

US20110218379A1 EPITOPES DERIVED FROM SATB2 AND USES THEREOF 有权
标题翻译：从SATB2衍生的衍生物及其用途
公开(公告)号：US20110218379A1
公开(公告)日：2011-09-08
申请号：US13062820
申请日：2009-10-06
申请人： Karin Jirsrtöm , Fredrik Pontén , Mathias Uhlén
发明人： Karin Jirsrtöm , Fredrik Pontén , Mathias Uhlén
IPC分类号： A61N5/00 , G01N33/68 , C07K16/18 , C07K7/06 , C07K7/08 , C07K14/47 , C07K1/14
CPC分类号： C07K14/4702 , C07K14/4748 , C07K16/18 , C07K16/22 , C07K2317/34 , G01N33/57419 , G01N2800/56
摘要： The present invention relates to an affinity ligand capable of selective interaction with an epitope sequence consisting of 47 amino acids or less and comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2. Further, it relates to a polypeptide consisting of the epitope sequence and to uses of the affinity ligand and the polypeptide.
摘要翻译：本发明涉及能够与由47个氨基酸或更少组成的表位序列选择性相互作用并且包含SEQ ID NO：1和/或SEQ ID NO：2的氨基酸序列的亲和配体。此外，它涉及由表位序列和亲和配体和多肽的用途组成的多肽。

7. 发明授权

US08420788B2 Epitopes derived from SATB2 and uses thereof 有权
标题翻译：衍生自SATB2的表位及其用途
公开(公告)号：US08420788B2
公开(公告)日：2013-04-16
申请号：US13062820
申请日：2009-10-06
申请人： Karin Jirström , Fredrik Pontén , Mathias Uhlén
发明人： Karin Jirström , Fredrik Pontén , Mathias Uhlén
IPC分类号： C07K16/00
CPC分类号： C07K14/4702 , C07K14/4748 , C07K16/18 , C07K16/22 , C07K2317/34 , G01N33/57419 , G01N2800/56
摘要： The present invention relates to an affinity ligand capable of selective interaction with an epitope sequence consisting of 47 amino acids or less and comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2. Further, it relates to a polypeptide consisting of the epitope sequence and to uses of the affinity ligand and the polypeptide.
摘要翻译：本发明涉及能够与由47个氨基酸或更少组成的表位序列选择性相互作用并且包含SEQ ID NO：1和/或SEQ ID NO：2的氨基酸序列的亲和配体。此外，它涉及由表位序列和亲和配体和多肽的用途组成的多肽。

8. 发明申请

US20120058202A1 Means and Method for Ovarian Cancer Prognosis 审中-公开
标题翻译：卵巢癌预后的手段和方法
公开(公告)号：US20120058202A1
公开(公告)日：2012-03-08
申请号：US13201740
申请日：2010-02-16
申请人： Mathias Uhlén , Fredrik Pontén , Karin Jirström , Donal J. Brennan
发明人： Mathias Uhlén , Fredrik Pontén , Karin Jirström , Donal J. Brennan
IPC分类号： A61K31/555 , C12Q1/68 , C40B30/04 , C07K16/18 , C07K14/47 , C07K7/06 , C07K4/12 , G01N33/574 , A61P35/00
CPC分类号： G01N33/689 , C07K14/4748 , G01N33/5743
摘要： There is provided a method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined refer-ence value; and if said sample value is higher than said ref-erence value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the sub-ject belongs to the second group. Related peptides, affinity ligands, uses and further methods are also provided.
摘要翻译：提供了一种用于确定具有卵巢癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤： a）评估早期从受试者获得的样品的至少一部分中的RBM3蛋白的量，并确定对应于评估量的样品值; b）将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）得出结论，所述受试者属于第一组; 并且如果所述样本值小于或等于所述参考值，则c2）推断子项目属于第二组。还提供了相关肽，亲和配体，用途和其它方法。

9. 发明申请

US20120219548A1 PODXL Protein in Colorectal Cancer 有权
标题翻译： PODXL蛋白在结肠直肠癌
公开(公告)号：US20120219548A1
公开(公告)日：2012-08-30
申请号：US13456354
申请日：2012-04-26
申请人： Karin Jirström , Mathias Uhlén , Fredrik Pontén
发明人： Karin Jirström , Mathias Uhlén , Fredrik Pontén
IPC分类号： G01N33/574 , A61P35/00 , A61K39/395
CPC分类号： G01N33/57419 , C07K16/22 , C07K16/3046 , C07K2317/76 , G01N2333/705 , G01N2333/90216 , G01N2800/52 , G01N2800/56
摘要： The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.
摘要翻译：本公开提供了一种用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤：：a）评估早先从受试者获得的样品的至少一部分中的PODXL蛋白的量，并确定与评估量相对应的样品值; b）将来自步骤a）的所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）认定所述对象属于所述第二组; 并且如果所述样本值小于或等于所述参考值，则c2）断定所述对象属于所述第一组。还提供了相关用途，手段和治疗方法。

10. 发明授权

US08067190B2 Use of protein SATB2 as a marker for colorectal cancer 有权
标题翻译：使用蛋白质SATB2作为结肠直肠癌的标志物
公开(公告)号：US08067190B2
公开(公告)日：2011-11-29
申请号：US12302248
申请日：2007-06-04
申请人： Mathias Uhlén , Fredrik Pontén
发明人： Mathias Uhlén , Fredrik Pontén
IPC分类号： G01N33/574 , G01N33/53
CPC分类号： G01N33/57419 , G01N2333/4703
摘要： The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.
摘要翻译：本发明通过鉴定SATB2蛋白作为该癌症类型的标志物，提供了与直肠癌的检测，表征和预后有关的新方法，手段和用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式